Patents by Inventor Kazuaki Takami
Kazuaki Takami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210087186Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: January 30, 2019Publication date: March 25, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Tomohiro OHASHI, Zenichi IKEDA, Yuta TANAKA, Florian PÜNNER, Takeshi YAMAMOTO, Keiko KAKEGAWA, Fumiaki KIKUCHI, Nao MORISHITA, Takahito KASAHARA, Masaki SETO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Satoshi MIKAMI, Minoru SASAKI
-
Patent number: 10807987Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 27, 2019Date of Patent: October 20, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Publication number: 20200270243Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: October 4, 2018Publication date: August 27, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinji NAKAMURA, Satoshi MIKAMI, Tomoaki HASUI, Tohru YAMASHITA, Shinji MORIMOTO, Hidekazu TOKUHARA, Norio OYABU, Masami YAMADA, Atsuko OCHIDA, Kazuaki TAKAMI, Xin LIU
-
Publication number: 20200157062Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasak
-
Publication number: 20200039957Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.Type: ApplicationFiled: March 29, 2018Publication date: February 6, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Kazuaki TAKAMI, Norihito TOKUNAGA, Tomohiro OKAWA, Akita SHIBUYA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
-
Patent number: 10544111Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: December 21, 2018Date of Patent: January 28, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20190300536Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: March 27, 2019Publication date: October 3, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
-
Publication number: 20190119225Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 10214498Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: October 22, 2015Date of Patent: February 26, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Yoshihiro Banno, Masahiro Kamaura, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Publication number: 20180237404Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: October 22, 2015Publication date: August 23, 2018Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro BANNO, Masahiro KAMAURA, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
-
Patent number: 9975903Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: GrantFiled: December 24, 2015Date of Patent: May 22, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
-
Patent number: 9944596Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: GrantFiled: October 22, 2015Date of Patent: April 17, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Banno, Masahiro Kamaura, Takahiko Taniguchi, Kazuaki Takami, Koichiro Fukuda, Shigekazu Sasaki
-
Patent number: 9890145Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: April 25, 2016Date of Patent: February 13, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
-
Publication number: 20170349605Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: December 24, 2015Publication date: December 7, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Minoru SASAKI, Fumiaki KIKUCHI, Zenichi IKEDA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Shigekazu SASAKI, Koichiro FUKUDA, Kazuaki TAKAMI, Yoshihiro BANNO, Masahiro KAMAURA
-
Publication number: 20170233339Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.Type: ApplicationFiled: October 22, 2015Publication date: August 17, 2017Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro BANNO, Masahiro KAMAURA, Takahiko TANIGUCHI, Kazuaki TAKAMI, Koichiro FUKUDA, Shigekazu SASAKI
-
Publication number: 20160311811Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: April 25, 2016Publication date: October 27, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Masato YOSHIDA, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
-
Patent number: 9321757Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: November 5, 2014Date of Patent: April 26, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi
-
Publication number: 20150133451Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: November 5, 2014Publication date: May 14, 2015Applicant: Takeda Pharmaceutical Company LimitedInventors: Masato Yoshida, Kazuaki TAKAMI, Yusuke TOMINARI, Zenyu SHIOKAWA, Akito SHIBUYA, Yusuke SASAKI, Tony GIBSON, Terufumi TAKAGI
-
Patent number: 8937055Abstract: The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.Type: GrantFiled: July 14, 2011Date of Patent: January 20, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Osamu Ujikawa, Kazuaki Takami, Nobuyuki Takakura, Nozomu Sakai
-
Publication number: 20130296276Abstract: The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.Type: ApplicationFiled: July 14, 2011Publication date: November 7, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Osamu UJIKAWA, Kazuaki TAKAMI, Nobuyuki TAKAKURA, Nozomu SAKAI